> top > docs > PubMed:23478169 > annotations

PubMed:23478169 JSONTXT

Annnotations TAB JSON ListView MergeView

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-98 Sentence denotes Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers.
TextSentencer_T2 99-110 Sentence denotes BACKGROUND:
TextSentencer_T3 111-324 Sentence denotes We previously reported the preliminary findings from a feasibility study of bladder cancer (BCa) screening with urinary molecular markers (Bladder Cancer Urine Marker Project [BLU-P]) that has now been terminated.
TextSentencer_T4 325-335 Sentence denotes OBJECTIVE:
TextSentencer_T5 336-442 Sentence denotes To report the final results from BLU-P to determine whether mass screening for BCa is feasible and useful.
TextSentencer_T6 443-563 Sentence denotes DESIGN, SETTING, AND PARTICIPANTS: BLU-P was a Dutch population-based study initiated in 2008 to evaluate BCa screening.
TextSentencer_T7 564-718 Sentence denotes A total of 6500 men were invited to participate in the study, 1984 (30.5%) agreed, and 1747 (88.1%) men completed the protocol and were followed for 2 yr.
TextSentencer_T8 719-732 Sentence denotes INTERVENTION:
TextSentencer_T9 733-1035 Sentence denotes The screening protocol included home hematuria testing followed by molecular markers-nuclear matrix protein 22 (NMP22), microsatellite analysis (MA), fibroblast growth factor receptor 3 (FGFR3) mutation snapshot assay, and a custom methylation-specific (MLPA) test-to determine the need for cystoscopy.
TextSentencer_T10 1036-1082 Sentence denotes OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS:
TextSentencer_T11 1083-1239 Sentence denotes Outcomes included the number of cystoscopies and the cancer detection rate within and outside the protocol, as determined by linkage to national registries.
TextSentencer_T12 1240-1264 Sentence denotes RESULTS AND LIMITATIONS:
TextSentencer_T13 1265-1352 Sentence denotes Overall, 409 men (23.4%) tested positive for hematuria and underwent molecular testing.
TextSentencer_T14 1353-1492 Sentence denotes Current smokers (n=295 [17%]) and past smokers (n=998 [58%]) were significantly more likely to test positive for hematuria than nonsmokers.
TextSentencer_T15 1493-1592 Sentence denotes Seventy-one of 75 men (94.6%) with positive molecular markers underwent the recommended cystoscopy.
TextSentencer_T16 1593-1751 Sentence denotes Four BCas and one kidney tumor were detected through this sequential protocol, whereas one BCa and one kidney tumor were missed through the screening program.
TextSentencer_T17 1752-1812 Sentence denotes Limitations include the possibility of healthy subject bias.
TextSentencer_T18 1813-1825 Sentence denotes CONCLUSIONS:
TextSentencer_T19 1826-2032 Sentence denotes For BCa screening, use of a sequential protocol with home hematuria testing followed by molecular markers substantially reduced the number of cystoscopy recommendations compared with dipstick testing alone.
TextSentencer_T20 2033-2152 Sentence denotes A sequential screening approach may help minimize unnecessary invasive follow-up testing, with very few missed cancers.
TextSentencer_T21 2153-2282 Sentence denotes Nevertheless, this mass screening program had a very low diagnostic yield in an unselected asymptomatic European male population.
T1 0-98 Sentence denotes Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers.
T2 99-110 Sentence denotes BACKGROUND:
T3 111-324 Sentence denotes We previously reported the preliminary findings from a feasibility study of bladder cancer (BCa) screening with urinary molecular markers (Bladder Cancer Urine Marker Project [BLU-P]) that has now been terminated.
T4 325-335 Sentence denotes OBJECTIVE:
T5 336-442 Sentence denotes To report the final results from BLU-P to determine whether mass screening for BCa is feasible and useful.
T6 443-563 Sentence denotes DESIGN, SETTING, AND PARTICIPANTS: BLU-P was a Dutch population-based study initiated in 2008 to evaluate BCa screening.
T7 564-718 Sentence denotes A total of 6500 men were invited to participate in the study, 1984 (30.5%) agreed, and 1747 (88.1%) men completed the protocol and were followed for 2 yr.
T8 719-732 Sentence denotes INTERVENTION:
T9 733-1035 Sentence denotes The screening protocol included home hematuria testing followed by molecular markers-nuclear matrix protein 22 (NMP22), microsatellite analysis (MA), fibroblast growth factor receptor 3 (FGFR3) mutation snapshot assay, and a custom methylation-specific (MLPA) test-to determine the need for cystoscopy.
T10 1036-1082 Sentence denotes OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS:
T11 1083-1239 Sentence denotes Outcomes included the number of cystoscopies and the cancer detection rate within and outside the protocol, as determined by linkage to national registries.
T12 1240-1264 Sentence denotes RESULTS AND LIMITATIONS:
T13 1265-1352 Sentence denotes Overall, 409 men (23.4%) tested positive for hematuria and underwent molecular testing.
T14 1353-1492 Sentence denotes Current smokers (n=295 [17%]) and past smokers (n=998 [58%]) were significantly more likely to test positive for hematuria than nonsmokers.
T15 1493-1592 Sentence denotes Seventy-one of 75 men (94.6%) with positive molecular markers underwent the recommended cystoscopy.
T16 1593-1751 Sentence denotes Four BCas and one kidney tumor were detected through this sequential protocol, whereas one BCa and one kidney tumor were missed through the screening program.
T17 1752-1812 Sentence denotes Limitations include the possibility of healthy subject bias.
T18 1813-1825 Sentence denotes CONCLUSIONS:
T19 1826-2032 Sentence denotes For BCa screening, use of a sequential protocol with home hematuria testing followed by molecular markers substantially reduced the number of cystoscopy recommendations compared with dipstick testing alone.
T20 2033-2152 Sentence denotes A sequential screening approach may help minimize unnecessary invasive follow-up testing, with very few missed cancers.
T21 2153-2282 Sentence denotes Nevertheless, this mass screening program had a very low diagnostic yield in an unselected asymptomatic European male population.

DisGeNET

Id Subject Object Predicate Lexical cue
T0 287-290 gene:7334 denotes BLU
T1 187-201 disease:C0005684 denotes bladder cancer
T2 287-290 gene:7334 denotes BLU
T3 187-201 disease:C0699885 denotes bladder cancer
T4 287-290 gene:51364 denotes BLU
T5 187-201 disease:C0005684 denotes bladder cancer
T6 287-290 gene:51364 denotes BLU
T7 187-201 disease:C0699885 denotes bladder cancer
T8 287-290 gene:7334 denotes BLU
T9 203-206 disease:C0005684 denotes BCa
T10 287-290 gene:7334 denotes BLU
T11 203-206 disease:C0699885 denotes BCa
T12 287-290 gene:51364 denotes BLU
T13 203-206 disease:C0005684 denotes BCa
T14 287-290 gene:51364 denotes BLU
T15 203-206 disease:C0699885 denotes BCa
T16 287-290 gene:7334 denotes BLU
T17 250-264 disease:C0005684 denotes Bladder Cancer
T18 287-290 gene:7334 denotes BLU
T19 250-264 disease:C0699885 denotes Bladder Cancer
T20 287-290 gene:51364 denotes BLU
T21 250-264 disease:C0699885 denotes Bladder Cancer
T22 287-290 gene:51364 denotes BLU
T23 250-264 disease:C0005684 denotes Bladder Cancer
T24 369-372 gene:51364 denotes BLU
T25 415-418 disease:C0699885 denotes BCa
T26 369-372 gene:51364 denotes BLU
T27 415-418 disease:C0005684 denotes BCa
T28 369-372 gene:7334 denotes BLU
T29 415-418 disease:C0699885 denotes BCa
T30 369-372 gene:7334 denotes BLU
T31 415-418 disease:C0005684 denotes BCa
T32 478-481 gene:51364 denotes BLU
T33 549-552 disease:C0699885 denotes BCa
T34 478-481 gene:51364 denotes BLU
T35 549-552 disease:C0005684 denotes BCa
T36 478-481 gene:7334 denotes BLU
T37 549-552 disease:C0699885 denotes BCa
T38 478-481 gene:7334 denotes BLU
T39 549-552 disease:C0005684 denotes BCa
R1 T0 T1 associated_with BLU,bladder cancer
R2 T2 T3 associated_with BLU,bladder cancer
R3 T4 T5 associated_with BLU,bladder cancer
R4 T6 T7 associated_with BLU,bladder cancer
R5 T8 T9 associated_with BLU,BCa
R6 T10 T11 associated_with BLU,BCa
R7 T12 T13 associated_with BLU,BCa
R8 T14 T15 associated_with BLU,BCa
R9 T16 T17 associated_with BLU,Bladder Cancer
R10 T18 T19 associated_with BLU,Bladder Cancer
R11 T20 T21 associated_with BLU,Bladder Cancer
R12 T22 T23 associated_with BLU,Bladder Cancer
R13 T24 T25 associated_with BLU,BCa
R14 T26 T27 associated_with BLU,BCa
R15 T28 T29 associated_with BLU,BCa
R16 T30 T31 associated_with BLU,BCa
R17 T32 T33 associated_with BLU,BCa
R18 T34 T35 associated_with BLU,BCa
R19 T36 T37 associated_with BLU,BCa
R20 T38 T39 associated_with BLU,BCa

Allie

Id Subject Object Predicate Lexical cue
SS1_23478169_2_0 187-201 expanded denotes bladder cancer
SS2_23478169_2_0 203-206 abbr denotes BCa
SS1_23478169_2_1 250-285 expanded denotes Bladder Cancer Urine Marker Project
SS2_23478169_2_1 287-292 abbr denotes BLU-P
SS1_23478169_9_0 810-843 expanded denotes markers-nuclear matrix protein 22
SS2_23478169_9_0 845-850 abbr denotes NMP22
SS1_23478169_9_1 853-876 expanded denotes microsatellite analysis
SS2_23478169_9_1 878-880 abbr denotes MA
SS1_23478169_9_2 883-918 expanded denotes fibroblast growth factor receptor 3
SS2_23478169_9_2 920-925 abbr denotes FGFR3
SS1_23478169_9_3 965-985 expanded denotes methylation-specific
SS2_23478169_9_3 987-991 abbr denotes MLPA
AE1_23478169_2_0 SS1_23478169_2_0 SS2_23478169_2_0 abbreviatedTo bladder cancer,BCa
AE1_23478169_2_1 SS1_23478169_2_1 SS2_23478169_2_1 abbreviatedTo Bladder Cancer Urine Marker Project,BLU-P
AE1_23478169_9_0 SS1_23478169_9_0 SS2_23478169_9_0 abbreviatedTo markers-nuclear matrix protein 22,NMP22
AE1_23478169_9_1 SS1_23478169_9_1 SS2_23478169_9_1 abbreviatedTo microsatellite analysis,MA
AE1_23478169_9_2 SS1_23478169_9_2 SS2_23478169_9_2 abbreviatedTo fibroblast growth factor receptor 3,FGFR3
AE1_23478169_9_3 SS1_23478169_9_3 SS2_23478169_9_3 abbreviatedTo methylation-specific,MLPA

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 187-201 HP_0009725 denotes bladder cancer
T2 195-201 HP_0002664 denotes cancer
T3 250-264 HP_0009725 denotes Bladder Cancer
T4 258-264 HP_0002664 denotes Cancer

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
23478169-3#0#3#gene7334 478-481 gene7334 denotes BLU
23478169-3#0#3#gene51364 478-481 gene51364 denotes BLU
23478169-3#71#74#diseaseC0005684 549-552 diseaseC0005684 denotes BCa
23478169-3#71#74#diseaseC0005695 549-552 diseaseC0005695 denotes BCa
23478169-3#71#74#diseaseC0699885 549-552 diseaseC0699885 denotes BCa
23478169-3#71#74#diseaseC0005684 549-552 diseaseC0005684 denotes BCa
23478169-3#71#74#diseaseC0005695 549-552 diseaseC0005695 denotes BCa
23478169-3#71#74#diseaseC0699885 549-552 diseaseC0699885 denotes BCa
0#3#gene733471#74#diseaseC0005684 23478169-3#0#3#gene7334 23478169-3#71#74#diseaseC0005684 associated_with BLU,BCa
0#3#gene733471#74#diseaseC0005695 23478169-3#0#3#gene7334 23478169-3#71#74#diseaseC0005695 associated_with BLU,BCa
0#3#gene733471#74#diseaseC0699885 23478169-3#0#3#gene7334 23478169-3#71#74#diseaseC0699885 associated_with BLU,BCa
0#3#gene733471#74#diseaseC0005684 23478169-3#0#3#gene7334 23478169-3#71#74#diseaseC0005684 associated_with BLU,BCa
0#3#gene733471#74#diseaseC0005695 23478169-3#0#3#gene7334 23478169-3#71#74#diseaseC0005695 associated_with BLU,BCa
0#3#gene733471#74#diseaseC0699885 23478169-3#0#3#gene7334 23478169-3#71#74#diseaseC0699885 associated_with BLU,BCa
0#3#gene5136471#74#diseaseC0005684 23478169-3#0#3#gene51364 23478169-3#71#74#diseaseC0005684 associated_with BLU,BCa
0#3#gene5136471#74#diseaseC0005695 23478169-3#0#3#gene51364 23478169-3#71#74#diseaseC0005695 associated_with BLU,BCa
0#3#gene5136471#74#diseaseC0699885 23478169-3#0#3#gene51364 23478169-3#71#74#diseaseC0699885 associated_with BLU,BCa
0#3#gene5136471#74#diseaseC0005684 23478169-3#0#3#gene51364 23478169-3#71#74#diseaseC0005684 associated_with BLU,BCa
0#3#gene5136471#74#diseaseC0005695 23478169-3#0#3#gene51364 23478169-3#71#74#diseaseC0005695 associated_with BLU,BCa
0#3#gene5136471#74#diseaseC0699885 23478169-3#0#3#gene51364 23478169-3#71#74#diseaseC0699885 associated_with BLU,BCa

DisGeNet-2017-sample

Id Subject Object Predicate Lexical cue
T1172 478-481 gene:7334 denotes BLU
T1173 549-552 disease:C0005684 denotes BCa
R1 T1172 T1173 associated_with BLU,BCa
R2 T1172 T1173 associated_with BLU,BCa
R3 T1172 T1173 associated_with BLU,BCa
R4 T1172 T1173 associated_with BLU,BCa
R5 T1172 T1173 associated_with BLU,BCa
R6 T1172 T1173 associated_with BLU,BCa

UBERON-AE

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 265-270 http://purl.obolibrary.org/obo/UBERON_0001088 denotes Urine
PD-UBERON-AE-B_T2 1611-1617 http://purl.obolibrary.org/obo/UBERON_0002113 denotes kidney
PD-UBERON-AE-B_T3 1696-1702 http://purl.obolibrary.org/obo/UBERON_0002113 denotes kidney

performance-test

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 1611-1617 http://purl.obolibrary.org/obo/UBERON_0002113 denotes kidney
PD-UBERON-AE-B_T2 1696-1702 http://purl.obolibrary.org/obo/UBERON_0002113 denotes kidney
PD-UBERON-AE-B_T3 265-270 http://purl.obolibrary.org/obo/UBERON_0001088 denotes Urine